S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Puma Biotechnology Stock Forecast, Price & News

+0.19 (+7.34%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.00 million shs
Average Volume
869,750 shs
Market Capitalization
$113.66 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PBYI News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Puma Biotechnology logo

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$225.10 million
Book Value
($0.15) per share


Net Income
$-59.99 million
Pretax Margin




Free Float
Market Cap
$113.66 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.30 out of 5 stars

Medical Sector

280th out of 1,417 stocks

Pharmaceutical Preparations Industry

124th out of 683 stocks

Analyst Opinion: 3.1Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

Is Puma Biotechnology a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Puma Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBYI, but not buy additional shares or sell existing shares.
View analyst ratings for Puma Biotechnology
or view top-rated stocks.

How has Puma Biotechnology's stock been impacted by COVID-19?

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PBYI shares have decreased by 70.0% and is now trading at $2.78.
View which stocks have been most impacted by COVID-19

Are investors shorting Puma Biotechnology?

Puma Biotechnology saw a increase in short interest during the month of November. As of November 30th, there was short interest totaling 3,100,000 shares, an increase of 22.5% from the November 15th total of 2,530,000 shares. Based on an average daily volume of 639,400 shares, the short-interest ratio is presently 4.8 days. Approximately 8.9% of the shares of the stock are short sold.
View Puma Biotechnology's Short Interest

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Puma Biotechnology

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.78. The biopharmaceutical company earned $46.20 million during the quarter, compared to analyst estimates of $53.44 million. Puma Biotechnology had a negative net margin of 19.29% and a negative trailing twelve-month return on equity of 665.45%. The company's quarterly revenue was down 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.79) EPS.
View Puma Biotechnology's earnings history

What price target have analysts set for PBYI?

4 Wall Street analysts have issued 1-year target prices for Puma Biotechnology's stock. Their forecasts range from $6.00 to $15.00. On average, they anticipate Puma Biotechnology's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 259.7% from the stock's current price.
View analysts' price targets for Puma Biotechnology
or view top-rated stocks among Wall Street analysts.

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the following people:

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG).

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include Patriot Financial Group Insurance Agency LLC (0.15%) and Diversified Trust Co (0.06%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends for Puma Biotechnology

Which major investors are buying Puma Biotechnology stock?

PBYI stock was purchased by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC, and Diversified Trust Co.
View insider buying and selling activity for Puma Biotechnology
or or view top insider-buying stocks.

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $2.78.

How much money does Puma Biotechnology make?

Puma Biotechnology has a market capitalization of $113.66 million and generates $225.10 million in revenue each year. The biopharmaceutical company earns $-59.99 million in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Puma Biotechnology have?

Puma Biotechnology employs 267 workers across the globe.

What is Puma Biotechnology's official website?

The official website for Puma Biotechnology is www.pumabiotechnology.com.

Where are Puma Biotechnology's headquarters?

Puma Biotechnology is headquartered at 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at [email protected], or via fax at 424-248-6501.

This page was last updated on 1/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.